These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

934 related items for PubMed ID: 18339640

  • 1. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [Abstract] [Full Text] [Related]

  • 2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD, Buckley CJ, Abrahamson EE, Kofler JK, Mathis CA, Klunk WE, Farrar G.
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [Abstract] [Full Text] [Related]

  • 3. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, Kraut MA, Ferrucci L, Mathis CA, Klunk WE, O'Brien RJ, Davatzikos C, Wong DF, Resnick SM.
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [Abstract] [Full Text] [Related]

  • 4. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
    Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR, Debnath ML, Cohen AD, Mizukami K, DeKosky ST, Lopez OL, Klunk WE.
    Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153
    [Abstract] [Full Text] [Related]

  • 5. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A.
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [Abstract] [Full Text] [Related]

  • 6. 11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous.
    Abrahamson EE, Kofler JK, Becker CR, Price JC, Newell KL, Ghetti B, Murrell JR, McLean CA, Lopez OL, Mathis CA, Klunk WE, Villemagne VL, Ikonomovic MD.
    Brain; 2022 Jun 30; 145(6):2161-2176. PubMed ID: 34918018
    [Abstract] [Full Text] [Related]

  • 7. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO.
    Arch Neurol; 2008 Oct 30; 65(10):1304-9. PubMed ID: 18695050
    [Abstract] [Full Text] [Related]

  • 8. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.
    Brain; 2014 Jun 30; 137(Pt 6):1762-71. PubMed ID: 24681664
    [Abstract] [Full Text] [Related]

  • 9. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.
    Neuroimage; 2010 Aug 15; 52(2):488-96. PubMed ID: 20385246
    [Abstract] [Full Text] [Related]

  • 10. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
    Chen CD, Joseph-Mathurin N, Sinha N, Zhou A, Li Y, Friedrichsen K, McCullough A, Franklin EE, Hornbeck R, Gordon B, Sharma V, Cruchaga C, Goate A, Karch C, McDade E, Xiong C, Bateman RJ, Ghetti B, Ringman JM, Chhatwal J, Masters CL, McLean C, Lashley T, Su Y, Koeppe R, Jack C, Klunk WE, Morris JC, Perrin RJ, Cairns NJ, Benzinger TLS.
    Acta Neuropathol; 2021 Oct 15; 142(4):689-706. PubMed ID: 34319442
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA, Langhough RE, Zammit MD, Clark L, Chin N, Christian BT, Betthauser TJ, Johnson SC.
    Brain; 2024 Jun 03; 147(6):2144-2157. PubMed ID: 38667631
    [Abstract] [Full Text] [Related]

  • 14. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics.
    den Haan J, Morrema THJ, Rozemuller AJ, Bouwman FH, Hoozemans JJM.
    Acta Neuropathol Commun; 2018 Aug 09; 6(1):75. PubMed ID: 30092839
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ, Koscik RL, Jonaitis EM, Allison SL, Cody KA, Erickson CM, Rowley HA, Stone CK, Mueller KD, Clark LR, Carlsson CM, Chin NA, Asthana S, Christian BT, Johnson SC.
    Brain; 2020 Jan 01; 143(1):320-335. PubMed ID: 31886494
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
    Lowe VJ, Lundt ES, Albertson SM, Przybelski SA, Senjem ML, Parisi JE, Kantarci K, Boeve B, Jones DT, Knopman D, Jack CR, Dickson DW, Petersen RC, Murray ME.
    Alzheimers Dement; 2019 Jul 01; 15(7):927-939. PubMed ID: 31175025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.